Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Nasopharyngeal Carcinoma 39Carcinoma, Non-Small-Cell Lung 30Carcinoma, Hepatocellular 23Esophageal Squamous Cell Carcinoma 22Triple Negative Breast Neoplasms 19Breast Neoplasms 18Squamous Cell Carcinoma of Head and Neck 17Advanced Solid Tumor 17Melanoma 15Stomach Neoplasms 14Small Cell Lung Carcinoma 13Colorectal Neoplasms 13Uterine Cervical Neoplasms 12Neoplasms 10Carcinoma, Transitional Cell 10Carcinoma, Renal Cell 10Recurrence 9Solid Tumor 7Sarcoma 7Neoplasm Metastasis 7Liver Neoplasms 7Head and Neck Neoplasms 7Esophageal Neoplasms 6Urinary Bladder Neoplasms 5Rectal Neoplasms 5Advanced Solid Tumors 5Pancreatic Neoplasms 4Laryngeal Neoplasms 4Hypopharyngeal Neoplasms 4Cholangiocarcinoma 4

Interventions

toripalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Primary Condition: Advanced Tumors × toripalimab × Clear all
NCT05650203 2023-04-05

A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies

Shanghai Junshi Bioscience Co., Ltd.

Phase 1 Withdrawn
Other neoplasm

Primary Condition: Advanced Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡